Cangrelor - a champion lost in translation?

Current guidelines recommend the early use of drugs that block platelet adenosine diphosphate (ADP) receptor P2Y12 in patients with acute coronary syndromes in whom percutaneous coronary intervention (PCI) may be performed.1 PCI is ultimately performed in 60 to 70% of patients with acute coronary syndromes who undergo diagnostic coronary angiography.2,3 The remaining patients are treated either medically or with urgent coronary-artery bypass grafting (CABG). An ideal ADP-receptor antagonist has to be potent and have a rapid onset and offset of antiplatelet action. The thienopyridines, clopidogrel and prasugrel, are ADP-receptor antagonists that have been approved by the Food and . . .

[1]  Deepak L. Bhatt,et al.  Intravenous platelet blockade with cangrelor during PCI. , 2009, The New England journal of medicine.

[2]  Gregg W Stone,et al.  Platelet inhibition with cangrelor in patients undergoing PCI. , 2009, The New England journal of medicine.

[3]  A. Schömig Ticagrelor--is there need for a new player in the antiplatelet-therapy field? , 2009, The New England journal of medicine.

[4]  Claes Held,et al.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.

[5]  J. Ware,et al.  Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. , 2009, European heart journal.

[6]  A. Kastrati,et al.  Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. , 2008, Journal of the American College of Cardiology.

[7]  E. Antman,et al.  Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.

[8]  Adelaide,et al.  Bivalirudin for patients with acute coronary syndromes. , 2006, The New England journal of medicine.

[9]  R. Wilcox,et al.  Open Multicentre Study of the P 2T Receptor Antagonist AR-C69931MX Assessing Safety, Tolerability and Activity in Patients with Acute Coronary Syndromes , 2001, Thrombosis and Haemostasis.